Physician profile
Nanda Biswas
NPI 1043316656
$28,281.69
in general payments reported to CMS, 2019-2025
75 companies · $4,696 in 2025
The $4,696 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,805 · 2020: $2,918 · 2021: $4,728 · 2022: $4,405 · 2023: $4,885 · 2024: $4,846 · 2025: $4,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $1,632 · Education: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,904.22 |
| Long Term Medical Supply Or Device Loan | $1,632.38 |
| Education | $889.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,897.30 | 2019-2025 | |
| Janssen Biotech, INC. | $2,180.46 | 2019-2025 | Darzalex, Imbruvica, Erleada |
| Astrazeneca Pharmaceuticals LP | $2,137.75 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,846.45 | 2019-2025 | Opdivo, Pomalyst, Reblozyl |
| Pfizer INC. | $1,597.84 | 2019-2025 | |
| Astellas Pharma US INC | $1,131.12 | 2019-2025 | Xtandi, Xospata, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $1,034.73 | 2019-2025 | |
| Incyte Corporation | $973.09 | 2019-2025 | Jakafi, Monjuvi, Monjuvi |
| Lilly USA, LLC | $725.50 | 2019-2025 | Verzenio, Mounjaro, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $659.89 | 2021-2025 | Libtayo |
| Celgene Corporation | $617.51 | 2021-2025 | Pomalyst, Reblozyl |
| Merck Sharp & Dohme LLC | $613.58 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Alexion Pharmaceuticals, INC. | $544.61 | 2020-2025 | Ultomiris |
| Puma Biotechnology, INC. | $525.65 | 2019-2025 | Nerlynx |
| Beigene USA, INC. | $518.86 | 2020-2025 | Brukinsa |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $516.10 | 2019-2024 | Zejula, Ojjaara, Trelegy Ellipta |
| Sobi, INC | $455.30 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $425.59 | 2020-2024 | Tavalisse, Rezlidhia |
| Novo Nordisk INC | $409.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pharmacyclics LLC, An Abbvie Company | $378.93 | 2019-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $356.16 | 2019-2025 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $292.49 | 2019-2023 | Iclusig, Ninlaro |
| Genentech USA, INC. | $274.33 | 2019-2025 | Tecentriq, Alecensa, Phesgo |
| Sanofi-Aventis U.S. LLC | $262.64 | 2019-2023 | |
| Seagen INC. | $256.99 | 2020-2023 | Adcetris, Tivdak |
| Amgen INC. | $254.65 | 2019-2024 | Repatha, Otezla, Vectibix |
| Ipsen Biopharmaceuticals, INC | $243.28 | 2024-2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.08 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $224.43 | 2021-2025 | Xpovio |
| Beone Medicines USA, INC. | $210.08 | 2025 | Brukinsa |
| Genzyme Corporation | $208.18 | 2020-2024 | |
| Emd Serono, INC. | $206.80 | 2020-2024 | Bavencio |
| Array Biopharma INC | $205.80 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Sumitomo Pharma America, INC. | $202.88 | 2023-2024 | Orgovyx |
| Janssen Pharmaceuticals, INC | $191.71 | 2019-2023 | Xarelto |
| Medicure Pharma INC. | $186.97 | 2020 | |
| Gilead Sciences, INC. | $186.85 | 2019-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $162.13 | 2024-2025 | Besremi |
| Agios Pharmaceuticals, INC. | $132.69 | 2025 | Pyrukynd |
| Sun Pharmaceutical Industries INC. | $131.63 | 2021-2023 | Odomzo, Yonsa |
| Myovant Sciences INC. | $130.68 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $116.72 | 2020-2024 | Oxlumo, Givlaari |
| Aveo Pharmaceuticals, INC. | $103.64 | 2022-2025 | Fotivda |
| Dova Pharmaceuticals | $93.31 | 2020-2021 | |
| Blue Earth Diagnostics | $87.41 | 2021-2025 | Posluma |
| Octapharma USA, INC. | $84.15 | 2023 | Octagam Immune Globulin (Human) |
| Apellis Pharmaceuticals, INC. | $81.69 | 2025 | Empaveli |
| Eisai INC. | $80.00 | 2021-2025 | |
| Daiichi Sankyo INC. | $67.78 | 2022-2023 | Enhertu |
| Stemline Therapeutics INC. | $67.59 | 2025 | Orserdu |
| Tolmar Pharmaceuticals, INC. | $58.14 | 2019-2022 | |
| Adc Therapeutics America, INC. | $54.79 | 2023-2025 | |
| Tesaro, INC. | $54.33 | 2019 | |
| Kite Pharma, INC. | $49.17 | 2020-2022 | |
| Clovis Oncology, INC. | $48.27 | 2020 | |
| Springworks Therapeutics, INC. | $43.25 | 2024-2025 | Ogsiveo |
| Azurity Pharmaceuticals, INC. | $40.11 | 2025 | Danziten, Vivimusta |
| Telix Pharmaceuticals | $37.82 | 2024 | Illuccix |
| Dendreon Pharmaceuticals LLC | $36.78 | 2019-2020 | |
| Legend Biotech USA INC. | $31.09 | 2025 | Carvykti |
| Coherus Oncology, INC. | $29.61 | 2022 | |
| Shield Therapeutics INC | $28.93 | 2025 | |
| Emmaus Medical, INC. | $27.16 | 2023 | Endari |
| Ferring Pharmaceuticals INC. | $24.40 | 2025 | Adstiladrin |
| Xeris Pharmaceuticals, INC. | $23.98 | 2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $22.68 | 2019 | |
| Redhill Biopharma INC. | $18.86 | 2024 | Talicia |
| Epizyme, INC. | $18.51 | 2021 | |
| Aurobindo Pharma USA, INC. | $18.11 | 2020 | |
| Immunogen, INC. | $17.65 | 2023 | Elahere |
| Taiho Oncology, INC. | $17.01 | 2020 | |
| Foundation Medicine, INC. | $16.78 | 2021 | |
| Mirati Therapeutics, INC. | $16.31 | 2023 | Krazati |
| Pharming Healthcare, INC. | $14.66 | 2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
Kisqali $1,685Imbruvica $711Brukinsa $680Lynparza $571Darzalex $533Imfinzi $516Nubeqa $427Erleada $412Xtandi $347Talvey $321Fabhalta $302Orgovyx $296Scemblix $296Pomalyst $291Keytruda $285Adcetris $283Libtayo $266Calquence $261Elrexfio $260Onivyde $243Rybrevant $225Opdivo $222Epkinly $206Ultomiris $203Tukysa $198Akeega $195Xofigo $194Braftovi $187Balversa $182Enhertu $174Xpovio $171Mektovi $166Stivarga $164Reblozyl $163Besremi $162Vonjo $159Breztri $156Jakafi $154Tagrisso $149Monjuvi $143Zejula $139Pyrukynd $133Bosulif $126Tecvayli $123Verzenio $120Doptelet $117Xospata $105Ibrance $101Rezlidhia $99.97Tavalisse $99.97Elitek $99.95Sarclisa $98.26Promacta $86.87Mounjaro $86.33Vyloy $85.56Octagam Immune Globulin (Human) $84.15Empaveli $81.69Rybelsus $79.25Ozempic $79.25Illuccix $75.64Piqray $71.13Orserdu $67.59Jaypirca $64.99Repatha $62.56Otezla $62.56Airsupra $60.06Iclusig $59.83Venclexta $54.45Tecentriq $54.27Pluvicto $51.90Vitrakvi $51.28Zynyz $49.47Fotivda $47.08Welireg $47.03Talzenna $46.22Ogsiveo $43.25Ojjaara $42.63Danziten $40.11Nerlynx $38.80Wegovy $37.23Posluma $34.50Zynlonta $33.19Carvykti $31.09Alecensa $30.90Trodelvy $29.72Tivdak $29.62Accrufer $28.93Oxlumo $28.61Tabrecta $28.34Kerendia $27.46Eliquis $27.40Endari $27.16Comirnaty $26.04Paxlovid $26.04Opdualag $25.93Oxbryta $25.69Padcev $25.06Givlaari $24.79Phesgo $24.63Adstiladrin $24.40
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanda Biswas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.